Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor

Top Cited Papers
Open Access
Abstract
In its most recent adult treatment panel report, the National Cholesterol Education Program recognized the metabolic syndrome (syndrome X; insulin resistance syndrome) as a new target of risk-reduction therapy.1 The metabolic syndrome is a cluster of closely associated and interdependent abnormalities, including insulin resistance, compensatory hyperinsulinemia, hyperuricemia, dyslipidemia, and hypertension,2 and predisposes individuals to type 2 diabetes, hypertension, and coronary heart disease (CHD).3,4

This publication has 27 references indexed in Scilit: